lamivudine HBV / Generic mfg. - LARVOL DELTA

Protective anti-HBs thresholds and risk of De Novo hepatitis B after pediatric liver transplantation using anti-HBc–positive donor grafts (TTS 2026) - "All infected patients were receiving lamivudine prophylaxis at the time of HBsAg positivity and had low anti-HBs levels (0–25 IU/L)... De novo HBV infection may occur despite antiviral prophylaxis when anti-HBs levels are insufficiently maintained. Sustained vaccination-based immunity combined with longitudinal anti-HBs monitoring appears critical for long-term protection in pediatric recipients of anti-HBc IgG–positive donor grafts."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Transplantation

Antiviral Management Patterns and Long-term Outcomes in HBsAg-Positive Kidney Transplant Recipients: A Retrospective Cohort Study (TTS 2026) - "However, comparative data on entecavir (ETV) monotherapy, ETV rescue therapy after prior lamivudine exposure, and self-discontinuation of antiviral therapy are limited... In this real-world cohort of HBsAg-positive KTRs, ETV monotherapy and ETV rescue therapy were associated with comparable long-term graft and patient survival. Self-discontinuation of antiviral therapy was associated with poorer unadjusted outcomes compared with continued ETV-based therapy, although this association was not statistically robust after adjustment. Continued ETV-based management was also associated with a more favorable long-term liver biochemical profile."

Retrospective data • Cardiovascular • Fibrosis • Hepatitis B • Hepatology • Hypertension • Immunology • Infectious Disease • Liver Failure • Transplantation

Thymosin-ɑ1 for people with chronic hepatitis B. (PubMed, Cochrane Database Syst Rev) - "We assessed the certainty of evidence as very low for all outcomes except for serious adverse events (low). Therefore, we are not sure whether thymosin-α1 monotherapy versus placebo or no intervention, or with the same co-interventions, reduces all-cause mortality, serious adverse events, HBV-related mortality, and non-serious adverse events, nor whether it has any effect on quality of life (based on one trial) and histological improvement. The effect of thymosin-ɑ1 on HBV-related morbidity is very uncertain. We observed no statistically significant differences between trials with and without cointerventions. We found no ongoing trials."

Clinical • Journal • Review • Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Oncology • Solid Tumor

High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis. (PubMed, Int J Mol Sci) - "Lamivudine-associated resistance (rtM204I/V) was the most common RT mutation detected in the overlapping RT/S region. HIV-infected individuals in southern Vietnam face a burden of both CHB and OBI, including a high proportion of seronegative OBI. The presence of seronegative OBI further supports the risk of underdiagnosis when relying only on standard serological markers, and reflects the need for integrated strategies combining highly sensitive serological assays with molecular diagnostics to improve HBV detection among high-risk populations."

Biomarker • Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Clinical and virological characteristics of hepatitis B virus genotype E infection: a case series. (PubMed, Infect Dis (Lond)) - "Lamivudine resistance mutations (L180M, M204V) were found in one (12.5%) case, tenofovir resistance-associated mutations (M267L/I) in two (25%) and immune escape mutations in three (37.5%), including T126I, D144E and G145R...In our setting, HBV genotype E infections largely occurred among migrants from endemic regions. Although nucleos(t)ide analogues are effective across genotypes, suboptimal adherence may hinder viral suppression and promote resistance."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Hepatitis B Reactivation After Kidney Transplantation in Hepatitis B Surface Antigen-Positive Recipients. (PubMed, Exp Clin Transplant) - "Although optimal duration of prophylactic antiviral therapy remains unclear, entecavir or tenofovir was the preferred antiviral therapy over lamivudine for hepatitis B virus reactivation prophylaxis. Close monitoring with antiviral prophylaxis is the optimal strategy to prevent hepatitis B virus reactivation during immunosuppressive therapy."

Biomarker • Journal • Retrospective data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Transplantation

Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration (AIDS 2026) - "We assessed CKD risks associated with (1) INSTIs vs non-nucleoside reverse transcriptase inhibitors (NNRTIs) and (2) TAF vs lamivudine (3TC), with both comparators considered kidney neutral...To account for artefactual creatinine increases when starting INSTIs and rilpivirine, baseline was defined as 6 months after starting treatment... After accounting for differences in participant characteristics, there was no increased CKD risk associated with INSTIs or TAF, although confidence intervals were relatively wide."

Cardiovascular • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • CD4

Prevention of HBV Mother-To-Child Transmission (MTCT) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda. (PubMed, J Viral Hepat) - "HVL mothers received Tenofovir Disoproxil Fumarate plus Lamivudine in the third trimester...Integrating maternal antiviral prophylaxis, targeted BD vaccination, and universal 3D vaccination achieved near-elimination of HBV MTCT in this setting. Nationally scaling this strategy could enable Uganda to meet the WHO target of less than 0.1% infant HBV prevalence before 2030 and serve as a model for other high-burden countries with significant rates of home births."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Expanding the Design Rules for Discriminating Nucleic Acid Mutations via Mismatch-Exchange. (PubMed, Angew Chem Int Ed Engl) - "Both selective tolerance to synonymous SNPs and OR-gate-based detection of clustered drug-resistant SNPs were demonstrated. Once deployed to nucleic acid testing in clinical settings, mismatch-exchange enabled the discrimination of multiple lamivudine-resistant hepatitis B virus mutants in a clinical cohort containing 65 clinical plasma samples."

Journal • Hepatitis B • Infectious Disease • Inflammation

Novel therapeutic strategy for HPV-negative Head and Neck cancer (AHNS 2026) - "To test this hypothesis, we generated radiation- and cisplatin-resistant HPV-negative HNSCC human and mouse cell lines in vitro and in vivo and evaluated the effects of the nucleoside reverse transcriptase inhibitor lamivudine...In immunocompetent murine models, lamivudine treatment exerted significant anti-tumor effect that was comparable 30Gy of fractionated radiotherapy, while combination of Lamivudine and radiation improved mouse survival. Collectively, these data indicate that LINE-1 is a promising therapeutic target for HPV-negative HNSCC."

Head and Neck Cancer • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Dynamics of spatiotemporal pharmacological models for hepatitis B virus infection under lamivudine and pegylated interferon alfa-2b therapies. (PubMed, BMC Infect Dis) - "Under treatment, the model predicts a progressive disappearance of infected patterns and a return toward spatial homogeneity. These findings highlight the crucial role of mathematical modeling in refining HBV treatment protocols and provide valuable insights for optimizing antiviral strategies."

Journal • Hepatitis B • Infectious Disease • Inflammation

MANAGEMENT OF DE NOVO HEPATITIS B RISK AFTER PEDIATRIC LIVER TRANSPLANTATION FROM ANTI-HBC IGG–POSITIVE DONORS (ESPGHAN 2026) - "Initial management included lamivudine in 26 recipients (89.7%), tenofovir in one(3.4%), and vaccination-based management without antivirals in two(6.9%)...In contrast, recipients managed with an immunization-based strategy alone did not develop HBV infection, suggesting that, in selected patients with sustained humoral immunity, vaccination-based management may represent a viable alternative to long-term antiviral prophylaxis. Contact e-mail address [email protected]"

Clinical • Breast Cancer • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Transplantation

Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV. (PubMed, AIDS) - "In recent years, the increasing use of tenofovir-sparing and lamivudine-sparing antiretroviral strategies, including dual and long-acting injectable regimens, has renewed concerns regarding this risk in individuals with serological evidence of prior exposure...In contrast, in individuals with sustained HIV virological suppression, preserved CD4+ cell counts, and markers of effective immune control, the absolute risk of clinically significant reactivation is low. These findings support a risk-based approach to antiretroviral simplification incorporating HBV serological history, vaccination status, and postswitch monitoring, rather than uniform restrictions on treatment switches in PWH with resolved HBV infection."

Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

LAMIVUDINE PROPHYLAXIS FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION IN HEMATOLOGIC PATIENTS UNDERGOING IMMUNOSUPPRESSIVE THERAPIES: A SINGLE-CENTER EXPERIENCE (EHA 2026) - "Current international guidelines (AASLD, EASL, NCCN) recommend entecavir or tenofovir as preferred agents for HBV prophylaxis, mainly because of the higher resistance rates observed with lamivudine (20–30% at 1–2 years versus approximately 1% at 5 years with entecavir)...Summary/Conclusion This study shows that lamivudine prophylaxis resulted in a low rate of HBVr and was safe in anti-HBc-positive hematologic patients undergoing immunosuppressive therapy. Despite current guideline preferences for newer antivirals, our findings suggest that lamivudine remains a reasonable and well-tolerated option."

Clinical • IO biomarker • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation

IDENTIFYING MF PATIENTS AT HIGH INFECTION RISK DURING RUXOLITINIB: THE HIDDEN ROLE OF TRANSFUSIONS, IRON OVERLOAD, AND INFLAMMATORY STATUS (EHA 2026) - "Antimicrobial prophylaxis (acyclovir/isoniazid/lamivudine) was used in 127 (13.1%) pts...These factors may help guide therapeutic choices, including anemia-directed approaches, and targeted prophylaxis. Cumulative Incidence Function of Infections estimated by Fine–Gray model (death as competing risk) by transfusion burden stratification."

Clinical • Hematological Disorders • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Myelofibrosis • Pneumococcal Infections • Respiratory Diseases • Septic Shock

Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma. (PubMed, World J Biol Chem) - "We analyze the effects of antivirals lamivudine, entecavir, tenofovir alafenamide, tenofovir disoproxil fumarate and immune-based strategies on reactivation after treatment for HBV-related HCC...This review recommends comparing the genome/proteome of blood from overt and relapsed HCC-related chronic HBV patients. This helps identifying persistent genetic/epigenetic profiles of HBV resistant variants, thus accurately selecting the appropriate antiviral therapy and eliminating the risk of viral reactivation."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B (EASL 2026) - "Lamivudine therapy provides durable long-term survival and HCC risk reduction, with safe cessation in selected patients and clear benefits of timely rescue therapy. These findings support optimization of CHB management strategies using current potent antiviral agents"

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Solid Tumor

The effect of Tenofovir on bone mineral density in liver transplant recipients (EASL 2026) - "In hepatitis B virus–related liver transplant recipients, tenofovir disoproxil fumarate (TDF) is widely used for post-transplant prophylaxis, but its effect on bone mineral density (BMD) remains unclear...Patients receiving TDF for ≥12 months were compared with those treated with entecavir or lamivudine... In hepatitis B–related liver transplant recipients, TDF use is associated with greater BMD loss than in controls during the early post transplant period and with an earlier onset of BMD loss during long-term follow-up.Although this bone loss does not appear to progress over time, the earlier development of osteoporosis highlights the need for close bone health monitoring.The FRAX score demonstrated moderate to good discriminatory performance for risk stratification in this population."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Transplantation

Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments (EASL 2026) - "Moreover, pevifoscorvir sodium (pevy), a prodrug of ALG-001075, has demonstrated potent reductions of HBV DNA, RNA, HBsAg, HBcrAg and HBeAg in subjects with CHB... Differentiated HepaRG cells were treated from day 6 post-infection with 1 µM ALG-001075 or lamivudine (3TC) for 1 month, then ALG-001075 was either continued for an additional month (arm 1) or stopped (arm 2) and cells monitored off-treatment for 4 weeks... Long term ALG-001075 treatment resulted in profound suppression of HBeAg, HBsAg and intracellular HBV RNAs which was durable after treatment withdrawal in HBV-infected HepaRG cells, suggesting a potential reduction in cccDNA level and/or transcriptional activity in these experimental conditions."

Hepatitis B • Infectious Disease

White Analytical Perspective on Lamivudine Determination: HPLC-PDA and HPLC-ELSD Method Development, Validation, and Multimetric Evaluation. (PubMed, ACS Omega) - "Although the HPLC-ELSD method showed slightly lower whiteness due to its higher LOQ and energy consumption, both proposed methods demonstrated acceptable analytical performance, applicability, and environmental compatibility. The developed approaches thus provide sustainable, reliable, and cost-effective analytical platforms consistent with the principles of WAC."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Multiple Sclerosis

HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort. (PubMed, Infect Dis Ther) - "One in five PWH lacked effective HBV immunity, including 41% of whom were receiving TXF-sparing strategies. In the context of increasing use of TXF-sparing strategies, improvements in systematic HBV screening, vaccination, and risk-based monitoring are essential to prevent HBV-related morbidity."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Evaluation of hepatitis B virus screening and reactivation in patients with hematological malignancies receiving rituximab-based chemoimmunotherapy: A single-center retrospective study. (PubMed, J Oncol Pharm Pract) - "The mean time to reactivation was 18.1 months after the start of chemoimmunotherapy, and one patient (0.2%) died of HBVr.ConclusionsThe findings highlight the critical importance of pretreatment HBV screening and prophylaxis to protect patients from the adverse consequences of reactivation. The study concludes that lamivudine may be a suitable prophylaxis option in selected patients."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Oncology

Real-World Experience of 25 Years of Lamivudine Therapy: Highlighting Favorable Long-Term Outcomes in Chronic Hepatitis B (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Use of Hepatitis B Virus (HBV)-Positive Organs (HBsAg+ or NAT+) for Heart Transplant (ISHLT 2026) - "Prophylaxis strategies included antiviral agents (entecavir and lamivudine) along with hepatitis B immune globulin (HBIG)...One of the five did seroconvert (new HBcAb+) after transplant despite prophylaxis, although the clinical significance of this is not clear given the patient never had significant signs or symptoms of infection and remains HBsAb+ and HBsAg-/NAT-.Conclusion This case series supports the feasibility of using HBV-positive donors for heart transplant with close monitoring. Further research is needed to determine appropriate prophylaxis strategies and assess long-term outcomes."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

Chronic Hepatitis B in Children Admitted to a Tertiary Hospital in Türkiye: A 23-Year Observational Study. (PubMed, J Med Virol) - "Patients who received treatment were classified into the following groups: interferon monotherapy; interferon plus lamivudine combination therapy; lamivudine; adefovir; tenofovir disoproxil fumarat; and entecavir...In our study, cirrhosis developed in 4 patients (1.2%) and hepatocellular cancer in 1 patient (0.3%). In our study, a significant proportion of treatment-naïve children exhibited moderate-to-severe liver fibrosis, highlighting the need for close monitoring and timely interventions; although current therapies achieve high response rates, more effective curative treatments are needed to prevent disease progression in pediatric hepatitis B."

Journal • Observational data • Retrospective data • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Liver Cancer • Liver Cirrhosis • Oncology • Pediatrics • Solid Tumor